Reminds me of Curis (CRIS) GDC-0449 with what they were able to achieve in their 50 person trial in Basal Cell Carcinoma. (Take a look at the NEJM article and pictures - QUITE amazing). -CRIS problem now is their drug has been pathetic in 2 major indications NOT driven by the hedgehog mutation.
Market Data 
Markets 
AI
